Analysts Expect Mesa Laboratories, Inc. (MLAB) to Post $2.13 EPS
Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price objective of $255.00 for the company and are anticipating that the company will post $2.13 EPS for the current quarter, according to Zacks. Zacks has also assigned Mesa Laboratories an industry rank of 106 out of 256 based on the ratings given to related companies.
Several research firms have recently weighed in on MLAB. ValuEngine raised shares of Mesa Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. BidaskClub raised shares of Mesa Laboratories from a “strong sell” rating to a “sell” rating in a research note on Friday, May 3rd. Zacks Investment Research raised shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $257.00 price target on the stock in a research note on Friday, February 8th. TheStreet raised shares of Mesa Laboratories from a “c” rating to a “b-” rating in a research note on Friday, February 8th. Finally, Sidoti began coverage on shares of Mesa Laboratories in a research note on Wednesday, March 13th. They set a “neutral” rating on the stock.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 31st will be paid a $0.16 dividend. The ex-dividend date of this dividend is Thursday, May 30th. This represents a $0.64 dividend on an annualized basis and a yield of 0.25%. Mesa Laboratories’s payout ratio is 10.36%.
In related news, Director David M. Kelly sold 684 shares of the stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $230.00, for a total value of $157,320.00. Following the sale, the director now directly owns 3,584 shares of the company’s stock, valued at approximately $824,320. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 15.00% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. One Wealth Advisors LLC acquired a new stake in Mesa Laboratories in the 1st quarter valued at about $72,000. Morgan Stanley grew its stake in Mesa Laboratories by 108.9% in the 1st quarter. Morgan Stanley now owns 19,574 shares of the medical instruments supplier’s stock valued at $4,511,000 after acquiring an additional 10,203 shares during the last quarter. Altshuler Shaham Ltd acquired a new stake in Mesa Laboratories in the 1st quarter valued at about $27,000. Wellington Management Group LLP grew its stake in Mesa Laboratories by 5.5% in the 1st quarter. Wellington Management Group LLP now owns 26,760 shares of the medical instruments supplier’s stock valued at $6,169,000 after acquiring an additional 1,391 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Mesa Laboratories in the 1st quarter valued at about $913,000. 71.84% of the stock is currently owned by hedge funds and other institutional investors.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.